Reeda Ismail

Nigeria’s pharmaceutical system is entering a defining moment. For decades, it has operated with fragmented coordination, limited manufacturing capacity, and heavy dependence on donor-driven delivery models. Today, these long-standing pressures have reached a critical point. The departure of global pharmaceutical companies, rising medicine prices and the approaching 2028 transition away from vaccine funding have created an environment where the system to confront realities can no longer be...